Contraceptive Technology Update
RSSArticles
-
Federal Agencies Issue More Family Planning Rules
Federal agencies are continuing to issue regulations and guidance with a sense of urgency, and, in several cases, the implications for family planning care may be profound.
-
Research Eyes Hormonal Contraceptive Use And Impact on Vitamin D Levels
Women risk having their vitamin D levels fall when they stop using birth control pills or other contraceptives containing estrogen, new research indicates. This finding has clinical implications when counseling women who are planning to conceive and identifying women who may be at risk of deficiency.
-
WHO Updates STI Treatment Guidance Due to Growing Antibiotic Resistance
The World Health Organization has issued new guidelines for the treatment of chlamydia, gonorrhea, and syphilis in response to the growing threat of antibiotic resistance. According to the international health organization, each year, 131 million people are infected with chlamydia, 78 million are infected with gonorrhea, and 5.6 million are infected with syphilis.
-
Deaths From Ovarian Cancer Fall Worldwide Due to Oral Contraceptive Use, Data Show
Deaths from ovarian cancer fell worldwide between 2002 and 2012 and are predicted to continue to decline through 2020 in the United States, European Union, and, to a lesser extent, in Japan, according to newly published research. The primary reason is the use of oral contraceptives and the long-term protection against ovarian cancer that they provide, say researchers.
-
LARC Options Expand With New Intrauterine Device
Family planning clinicians are adding another choice to the expanding list of long-acting reversible contraceptive options with the September 2016 FDA approval of the Kyleena 19.5 mg levonorgestrel IUD from Whippany, NJ-based Bayer HealthCare Pharmaceuticals. The new IUD is available as of October 2016 by prescription only.
-
U.S. Preventive Services Task Force Recommends Against Genital Herpes Screening
The CDC estimates that about one in six U.S. residents ages 14-49 has genital herpes.1 In new draft guidance, the U.S. Preventive Services Task Force (USPSTF) recommends against using current blood tests to screen for genital herpes in people with no signs or symptoms of infection, including adolescents and adults, as well as pregnant women.2
-
The Trajectories of Vasomotor Symptoms Eyed Across the Menopausal Transition
Most women will get hot flashes or night sweats at some point during menopause. Research indicates 42% to 79% of women experience vasomotor symptoms (VMSs) during the menopausal transition.1-4 Just-published findings show that women fit into four distinct groups when it comes to having hot flashes and night sweats, which offers potential ramifications for therapy and prevention of future health conditions, according to research led by the Graduate School of Public Health at the University of Pittsburgh.5
-
Counsel on Convenience and Effectiveness Of Immediate Postpartum LARC
Unplanned pregnancies can happen in the postpartum period. Data indicate 40-57% of women report having unprotected intercourse before the routine six-week postpartum visit.1,2 The American College of Obstetricians and Gynecologists (ACOG) has just issued a new committee opinion on the use of long-acting reversible contraception (LARC) in the postpartum period to help stem such pregnancies.3
-
Combined Hormonal Contraception and Migraine — Add Clinical Information to Your Practice
What do you know when it comes to prescribing combined hormonal methods for women with migraines? A new two-part Association of Reproductive Health Professionals webinar series, “Migraines & the Female Patient,” offers information on the epidemiology of migraines and how to counsel affected women on their contraceptive options.
-
Get the Latest Guidance on Zika Virus In the Family Planning Setting
Clinicians can get up to speed on the latest strategies for Zika virus prevention, as well as implement the latest guidance surrounding Zika in the family planning setting, with new webinars hosted by the American College of Obstetricians and Gynecologists (ACOG) and the CDC.